Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Paul Angulo, David E. Kleiner, Sanne Dam‐Larsen et al. · Gastroenterology · 2015 · 3K citations · Full text

Medicine, Internal Medicine, Pathology +12

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014 · 2.3K citations · Full text

Medicine, Internal Medicine, Pathology +17

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

Medicine, Internal Medicine, Pharmacology +14